All In Biotech

Drug Trial Radar · NCT03604198

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

125

Actual

Start

May 7, 2018

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.

Conditions

  • Cushing Syndrome

Interventions

  • relacorilantDrug

    CORT125134 is supplied as capsules for oral dosing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term safety of relacorilantTime frame: 36 months

Locations

48 sites in 10 countries. Site status is shown where the registry gives one.

  • Site 49

    Phoenix, Arizona

  • Site 35

    Stanford, California

  • Site 39

    Torrance, California

  • Site 50

    Miami, Florida

  • Site 10

    Atlanta, Georgia

  • Site 9

    Chicago, Illinois

  • Site 1

    Indianapolis, Indiana

  • Site 5

    Metairie, Louisiana

  • Site 27

    Baltimore, Maryland

  • Site 13

    Fall River, Massachusetts

  • Site 8

    Ann Arbor, Michigan

  • Site 36

    Rochester, Minnesota

  • Site 34

    Jackson, Mississippi

  • Site 3

    St Louis, Missouri

  • Site 55

    Reno, Nevada

  • Site 6

    Albany, New York

  • Site 24

    New York, New York

  • Site 4

    Wilmington, North Carolina

  • Site 43

    Cleveland, Ohio

  • Site 2

    Pittsburgh, Pennsylvania

  • Site 46

    Pittsburgh, Pennsylvania

  • Site 11

    Dallas, Texas

  • Site 7

    El Paso, Texas

  • Site 32

    Fort Worth, Texas

  • Site 12

    Houston, Texas

  • Site 14

    Vienna, Austria

  • Site 51

    Nova Scotia, Canada

  • Site 16

    Munich, Germany

  • Site 42

    Würzburg, Germany

  • Site 20

    Ramat Gan, Israel

  • Site 29

    Tel Aviv, Israel

  • Site 40

    Ancona, Italy

  • Site 44

    Messina, Italy

  • Site 25

    Milan, Italy

  • Site 21

    Naples, Italy

  • Site 48

    Padova, Italy

  • Site 52

    Torino, Italy

  • Site 33

    Rotterdam, Netherlands

  • Site 47

    Krakow, Poland

  • Site 45

    Lublin, Poland

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.